Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.

Gregory P. Hess,C. Chen,Zhimei Liu,Dean Gesme,Sanjiv S. Agarwala,Jerrold Hill

Risk of treatment failure after first-line tyrosine kinase inhibitors (TKI) therapy in patients with metastatic renal cell carcinoma.

2011

Gregory P. Hess
C. Chen
Zhimei Liu
Dean Gesme
Sanjiv S. Agarwala
Jerrold Hill

e15114 Background: Treatment for metastatic renal cell carcinoma (mRCC) includes surgery, immunotherapy, and/or targeted therapy: kinase inhibitors (including mTOR) and anti-VEGF agents. This analy...

Keywords:

Tyrosine kinase
Pathology
Renal cell carcinoma
Cancer research
Internal medicine
Oncology
Medicine
first line
PI3K/AKT/mTOR pathway
Kinase
Targeted therapy
Immunotherapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations